Together, the findings indicate that the SAMD9/MYH9/GSK3β/β‐catenin axis promotes ESCC postoperative recurrence and that SAMD9 is a crucial target for ESCC therapy. The gene discussed is MYH9; the disease is esophageal squamous cell carcinoma.